XP-102 and XP-102 in Combination With Trametinib in Advanced Solid Tumor Patients With a BRAF V600 Mutation

PHASE1/PHASE2Not yet recruitingINTERVENTIONAL

Enrollment

221

Participants

Timeline

Start Date

December 31, 2025

Primary Completion Date

December 30, 2027

Study Completion Date

December 30, 2028

Conditions

CancerBRAF V600 MutationMelanomaColorectal CancerThyroid CancerNonsmall Cell Lung Cancer

Interventions

DRUG

XP-102

XP-102 will be administered orally once or twice daily in a continuous regimen.

DRUG

Trametinib

Trametinib will be administered 2mg orally once a day.

All Listed Sponsors

lead

Xynomic Pharmaceuticals, Inc.

INDUSTRY